ArticlemAbs
Improved stability of multivalent antibodies containing the human collagen XV trimerization domain.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Anti-angiogenic therapies in cancer: from endogenous inhibitors to bispecific VEGF x PD-(L)1 antibodies.Frontiers in immunology · 2026Review
- Article
- Development of a nanobody-based immunoassay for the analysis of the disinfectant triclosan in water.Talanta · 2025Article
- A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.Oncoimmunology · 2023Article
- Critical parameters for design and development of multivalent nanoconstructs: recent trends.Drug delivery and translational research · 2022Review
- Review
- Collagen XV, a multifaceted multiplexin present across tissues and species.Matrix biology plus · 2020Article
- Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies.Frontiers in immunology · 2019Article
- A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.Nature communications · 2018Article
- A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system.BMC biotechnology · 2018Article
- Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging.The Journal of biological chemistry · 2018Article
- Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains.Scientific reports · 2016Article
- Bacterial secretion of soluble and functional trivalent scFv-based N-terminal trimerbodies.AMB Express · 2015Article
- Efficient production of single-chain fragment variable-based N-terminal trimerbodies in Pichia pastoris.Microbial cell factories · 2014Article
- Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Tribody: robust self-assembled trimeric targeting ligands with high stability and significantly improved target-binding strength.Biochemistry · 2013Article
- Article
- Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications.OncoimmunologyArticle
- Article
- Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We recently described the in vitro and in vivo properties of an engineered homotrimeric antibody made by fusing the N-terminal trimerization region of collagen XVIII NC1 domain to the C-terminus of a scFv fragment [trimerbody (scFv-NC1) 3; 110 kDa]. Here, we demonstrated the utility of the N-terminal trimerization region of collagen XV NC1 domain in the engineering of trivalent antibodies. We constructed several scFv-based trimerbodies containing the human type XV trimerization domain and demonstrated that all the purified trimerbodies were trimeric in solution and exhibited excellent antigen binding capacity. Importantly, type XV trimerbodies demonstrated substantially greater thermal and serum stability and resistance to protease digestion than type XVIII trimerbodies. In summary, the small size, high expression level, solubility and stability of the trimerization domain of type XV collagen make it the ideal choice for engineering homotrimeric antibodies for cancer detection and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.